Alzheimers Disease and Associated Indications: Exceptional Level of First-in-Class Innovation and Diverse Range of Therapies in Development

ResearchMoz added Latest Research Report titled " Frontier Pharma: Alzheimers Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression " to it's Large Report database.

Alzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable disease characterized by loss of memory and other mental abilities. It has a devastating impact on independence and quality of life, with patients requiring full-time care in the later disease stages. In addition to cognitive impairment, AD is associated with behavioral and psychological changes, which often represent the greatest challenges for patients and caregivers.

The prevalence of AD is escalating rapidly, largely owing to aging populations, as advancing age is the most important epidemiological risk factor for the disease. This will amplify the already substantial societal and economic costs of the disease over the coming years. This has led to high levels of R&D investment over the past two decades, but clinical trial failure rates within the indication are extremely high and treatment options remain limited. There are no disease-modifying therapies for AD, and current approaches can only temporarily slow the worsening of symptoms.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1135804

The report focuses on AD alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden.

Scope

Unmet need is extremely high in AD, with behavioral and psychological complications contributing significantly to the disease burden
What are the most important etiological risk factors and pathophysiological processes implicated in AD?
What is the current treatment algorithm?
How common are anxiety, depression, psychosis and insomnia in AD?
The AD pipeline is large and contains a very high proportion of first-in-class product innovation
Which molecule types and molecular targets are most prominent across AD and its associated indications?
What are the connections, in terms of first-in-class innovation, between AD and its associated indications?
Which first-in-class targets are most promising?
How does the level of first-in-class innovation differ between products in development for anxiety, depression, psychosis and insomnia?
How does first-in-class target diversity differ by stage of development and molecular target class?

Browse more details @ http://www.researchmoz.us/frontier-pharma-alzheimers-disease-and-associated-indications-exceptional-level-of-firstinclass-innovation-within-ad-and-diverse-range-of-therapies-in-development-for-disorders-such-as-anxiety-and-depression-report.html

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Executive Summary 6
2.1 Limited Treatment Options despite Large Market Opportunity 6
2.2 Exceptionally High Level of First-in-Class Innovation within Alzheimer’s Disease Pipeline 6
2.3 Active Deals Landscape Dominated by GPCR-Targeting Products 6

3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic Products 8
3.2 Diversification of Molecular Targets 8
3.3 Innovative First-in-Class Product Developments Remain Attractive 9
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 9
3.5 Sustained Innovation in Alzheimer’s Disease 10
3.6 GBI Research Report Guidance 10

4 Clinical and Commercial Landscape 12
4.1 Disease Overview 12
4.2 Classification of Dementia and Mild Cognitive Impairment 12
4.3 Symptoms, Disease Staging and Prognosis 13

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

This release was published on openPR.